南昌双向情感障碍那家好南昌市第十二医院看精神科收费怎么样,南昌治疗焦虑症最好的中医医院,在南昌看精神哪家医院好,南昌哪里看精神病较好的,南昌市治疗失眠的医院哪家好,南昌有名精神障症医院,南昌失眠哪儿专业

UNITED NATIONS, Oct. 17 (Xinhua) -- China on Monday underlined the importance of safeguarding the peaceful use of outer space and preventing the weaponization of and an arms race in outer space, saying that "the outer space is the common wealth of mankind as the global public space."The statement came as Wang Qun, the Chinese ambassador for disarmament affairs, was taking the floor at the thematic debate on outer space at the First Committee of the UN General Assembly. The First Committee is in charge of disarmament and international security."The outer space is the common wealth of mankind as the global public space," Wang said. "The permanent peace of outer space is correlated to all nations' security, development and prosperity.""Meanwhile, with the growing reliance of mankind on outer space, the risk of the weaponization of and an arms race in outer space are on rise, and the uncertainties concerning outer space security are accumulating as well," he said. "Safeguarding the peaceful use of outer space and preventing the weaponization of and an arms race in outer space are common interest and obligations of all countries."In responding to the growing challenge for security in outer space, the international community also witnessed common grounds on opposing to the weaponization of outer space and advertising the Prevention of an Arms Race in Outer Space, he said.The General Assembly, for consecutive years, adopted " Prevention of an Arms Race in Outer Space" resolution by overwhelming majority of votes, calling for negotiations on an international legally-binding instrument on the prevention of an arms race in outer space at the Conference on Disarmament in Geneva."The mankind has marched into the 6th decade of outer space exploitation, and the manned space flight has made a history of 50 years," Wang said."Recently, China has successfully launched the Tiangong-1 ( Heavenly Palace 1) as a target spacecraft for rendezvous and docking experiment, which opens a new era of China's manned space flight, and also reflects that China is committed itself to the honorable objective of promoting the peaceful exploration and utilization of the outer space, maintaining peace and bringing benefit to mankind."

NEW YORK, Dec. 1 (Xinhua) -- New York City Mayor Michael Bloomberg announced on Thursday a new recommendation that doctors offer every person with an HIV diagnosis antiretroviral treatment to help them live longer and prevent transmission.This marks a change from the current practice that treatment only be offered to those who show signs of damage to their immune systems, said the mayor during the annual World AIDS Day commemorative ceremony at Gracie Mansion. "Over the past ten years HIV diagnoses and deaths in New York City have seen a dramatic decline," said Mayor Bloomberg. "Steady progress in our fight against HIV has turned what used to be a death sentence into a disease that can be prevented and, with antiretroviral therapy, managed.The annual death toll from HIV in the city is down by more than a third: 933 deaths in 2009Despite this progress, however, more than 110,000 people in New York City are infected with HIV, more than in any other U.S. city and about 75 percent of all cases in the New York State.Figures from the New York City Health and Hospitals Corporation (HHC) showed that HHC has tested more than one million New Yorkers for HIV since 2005 when the public hospitals and health centers began offering HIV screening as a routine part of medical care for patients aged 13 to 64.

BEIJING, Jan. 20 (Xinhua) -- China will regulate the production and sale of cosmetic colored contact lenses by including them in its list of items classified as "medical apparatus."Some people wear such non-corrective colored contacts to change or enhance eye color for cosmetic and fashion purposes.As these contacts are not for vision correction and medication purposes, they are currently off limits to the country's medical administration and regulators, said a statement published on the website of the State Food and Drug Administration on Thursday.However, with the increasingly popular use of cosmetic contacts, safety and quality problems due to the regulation loophole are likely to harm consumers' health, and the administration has decided to expand the current medical regulation on contact lenses to cover cosmetic ones, the statement said.It explained that the administration will soon issue a notice to ban the manufacture and sale of these contacts without proper registration and licenses.The statement also warned consumers of the risks of these contacts and suggested they carefully choose and use such products.

BEIJING, Jan. 7 (Xinhua) -- The two-day National Financial Work Conference concluded Saturday, laying out development plans for the financial sector in the coming five years, according to a statement released after the meeting.Chinese Premier Wen Jiabao was present at the conference and delivered a keynote speech.Such a conference is held every five years. Similar meetings were held in 1997, 2002 and 2007.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.